Benjamin D. Stein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Benjamin D. Stein has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Lewis Clayton Cantley
Department of Cell Biology, Harvard Medical School, Boston, USA
48 shared publications - Eric Edison Gardner
Meyer Cancer Center, Weill Cornell Medicine
47 shared publications - Harold Varmus
Meyer Cancer Center, Weill Cornell Medicine
47 shared publications - Raymond E. Moellering
Department of Chemistry The University of Chicago Chicago Illinois USA
47 shared publications - David Wu
Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York
46 shared publications - Chen Zhang
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
45 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S2. Phosphorylation of human TPI1 is LKB1-dependent.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S2. Phosphorylation of human TPI1 is LKB1-dependent.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S1. Differential co-occurrence and effects of KRAS, TP53 and LKB1 mutations on human and mouse LUADs.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S1. Differential co-occurrence and effects of KRAS, TP53 and LKB1 mutations on human and mouse LUADs.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S5. LKB1 regulates the multimeric state of hTPI1 but not mTpi1 and substitution of Cys in hTPI1 causes formation of a covalent TPI1 dimer.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S5. LKB1 regulates the multimeric state of hTPI1 but not mTpi1 and substitution of Cys in hTPI1 causes formation of a covalent TPI1 dimer.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S3. TPI1 phosphorylation regulates triose phosphate levels and metabolic flux.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S3. TPI1 phosphorylation regulates triose phosphate levels and metabolic flux.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S6. TPI1 allelic variants effects central carbon metabolic flux.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S6. TPI1 allelic variants effects central carbon metabolic flux.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S4. Members of the salt Inducible kinase family phosphorylate TPI1.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S4. Members of the salt Inducible kinase family phosphorylate TPI1.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S8. Tpi1 inactivation in KL autochthonous tumor model alters histology and pathology.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S8. Tpi1 inactivation in KL autochthonous tumor model alters histology and pathology.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
- Top Cited Papers
- 9 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 383 (6683) , eadj1415
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
Lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) are thought to originate from different epithelial cell types in the lung. Intriguingly, LUAD can histologically transform into SCLC after treatment with targeted therapies. In this study, we designed models to follow the conversion of LUAD to SCLC and found that the barrier to histological transformation converges on tolerance to Myc, which we implicate as a lineage-specific driver of the pulmonary neuroendocrine cell. Histological transformations are frequently accompanied by activation of the Akt pathway. Manipulating this pathway permitted tolerance to Myc as an oncogenic driver, producing rare, stem-like cells that transcriptionally resemble the pulmonary basal lineage. These findings suggest that histological transformation may require the plasticity inherent to the basal stem cell, enabling tolerance to previously incompatible oncogenic driver programs.
- 9 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 383 (6683) , eadj1415
Top Cited PapersLineage-specific intolerance to oncogenic drivers restricts histological transformation
Lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) are thought to originate from different epithelial cell types in the lung. Intriguingly, LUAD can histologically transform into SCLC after treatment with targeted therapies. In this study, we designed models to follow the conversion of LUAD to SCLC and found that the barrier to histological transformation converges on tolerance to Myc, which we implicate as a lineage-specific driver of the pulmonary neuroendocrine cell. Histological transformations are frequently accompanied by activation of the Akt pathway. Manipulating this pathway permitted tolerance to Myc as an oncogenic driver, producing rare, stem-like cells that transcriptionally resemble the pulmonary basal lineage. These findings suggest that histological transformation may require the plasticity inherent to the basal stem cell, enabling tolerance to previously incompatible oncogenic driver programs.
- Open Access
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
Lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) are thought to originate from different epithelial cell types in the lung. Intriguingly, LUAD can histologically transform into SCLC following treatment with targeted therapies. Here we designed models to follow the conversion of LUAD to SCLC and found the barrier to histological transformation converges on tolerance to Myc, which we implicate as a lineage-specific driver of the pulmonary neuroendocrine cell. Histological transformations are frequently accompanied by activation of the Akt pathway. Manipulating this pathway permitted tolerance to Myc as an oncogenic driver, producing rare, stem-like cells, transcriptionally resembling the pulmonary basal lineage. These findings suggest histological transformation may require the plasticity inherent to the basal stem cell, enabling tolerance to previously incompatible oncogenic driver programs. One-Sentence Summary By modeling histological transformation of lung cancer, we uncover neuroendocrine-specific tolerance to Myc as an oncogenic driver.
Open AccessLineage-specific intolerance to oncogenic drivers restricts histological transformation
Lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) are thought to originate from different epithelial cell types in the lung. Intriguingly, LUAD can histologically transform into SCLC following treatment with targeted therapies. Here we designed models to follow the conversion of LUAD to SCLC and found the barrier to histological transformation converges on tolerance to Myc, which we implicate as a lineage-specific driver of the pulmonary neuroendocrine cell. Histological transformations are frequently accompanied by activation of the Akt pathway. Manipulating this pathway permitted tolerance to Myc as an oncogenic driver, producing rare, stem-like cells, transcriptionally resembling the pulmonary basal lineage. These findings suggest histological transformation may require the plasticity inherent to the basal stem cell, enabling tolerance to previously incompatible oncogenic driver programs. One-Sentence Summary By modeling histological transformation of lung cancer, we uncover neuroendocrine-specific tolerance to Myc as an oncogenic driver.